GenMark Diagnostics Reports Fourth Quarter and Full Year 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- US stock index futures slip as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
Needham & Company Reiterates Buy on GenMark Diagnostics (GNMK) Following 4Q
March 1, 2017 7:34 AM ESTNeedham & Company reiterated a Buy rating and $15.00 price target on GenMark Diagnostics (NASDAQ: GNMK) following the company's 4Q earnings report. GNMK's 4Q16 revenue was $14.9M. And its GAAP EPS was ($0.27) vs. consensus of ($0.27).
Analyst Mike Matson commented, "GNMK's 4Q16 revenue was consistent with... More
GenMark Diagnostics (GNMK) Reports In-Line Q4 EPS
February 28, 2017 4:23 PM ESTGenMark Diagnostics (NASDAQ: GNMK) reported Q4 EPS of ($0.27), in-line with the analyst estimate of ($0.27). Revenue for the quarter came in at $14.9 million versus the consensus estimate of $14.83 million.
For earnings history and earnings-related data on GenMark Diagnostics (GNMK) click here.
... More